This translational background explains recent clinical findings in advanced cancer patients who had improved responses and survival outcomes after VEGF/VEGF receptor (VEGFR) inhibitor therapy mostly in tumors harboring a TP53 mutation [11,12,13,14,15]. Here, TP53 is linked to cancer.